Area of research
Psychiatry and Mental health · Cognitive Neuroscience
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Memory and Neural Mechanisms, and Functional Brain Connectivity Studies.
Entorhinal‐based path integration selectively predicts midlife risk of Alzheimer's disease
Cytokine expression patterns predict suppression of vulnerable neural circuits in a mouse model of Alzheimer’s disease
Apolipoprotein E ε4 modulates astrocyte neuronal support functions in the presence of amyloid-β.
Assessing mild cognitive impairment using object‐location memory in immersive virtual environments
Predictive link between systemic metabolism and cytokine signatures in the brain of apolipoprotein E ε4 mice
Apolipoprotein E4 modulates astrocyte neuronal support functions in the presence of amyloid-β
Pathogen-specific antimicrobials engineered de novo through membrane-protein biomimicry.
Mild Cognitive Impairment: the Manchester consensus
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis
European Ultrahigh‐Field Imaging Network for Neurodegenerative Diseases (EUFIND)
Lifestyle activities in mid-life contribute to cognitive reserve in late-life, independent of education, occupation, and late-life activities
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP
Progression of brain atrophy in PSP and CBS over 6 months and 1 year
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
THE MS-STAT TRIAL: High Dose Simvastatin Slows Brain Atrophy and Delays Disability in Secondary Progressive Multiple Sclerosis: A Phase II Placebo-Controlled Trial (PL02.001)